Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of camrelizumab for primary liver cancer
ChiCTR2000031838Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000031838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031838.